IL299750A - Lipid nanoparticles for the delivery of therapeutic agents to the lungs - Google Patents

Lipid nanoparticles for the delivery of therapeutic agents to the lungs

Info

Publication number
IL299750A
IL299750A IL299750A IL29975023A IL299750A IL 299750 A IL299750 A IL 299750A IL 299750 A IL299750 A IL 299750A IL 29975023 A IL29975023 A IL 29975023A IL 299750 A IL299750 A IL 299750A
Authority
IL
Israel
Prior art keywords
lungs
lipid nanoparticles
delivering therapeutics
therapeutics
delivering
Prior art date
Application number
IL299750A
Other languages
English (en)
Hebrew (he)
Original Assignee
Genevant Sciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genevant Sciences Gmbh filed Critical Genevant Sciences Gmbh
Publication of IL299750A publication Critical patent/IL299750A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL299750A 2020-07-10 2021-07-08 Lipid nanoparticles for the delivery of therapeutic agents to the lungs IL299750A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063050594P 2020-07-10 2020-07-10
PCT/US2021/040913 WO2022011156A1 (en) 2020-07-10 2021-07-08 Lipid nanoparticles for delivering therapeutics to lungs

Publications (1)

Publication Number Publication Date
IL299750A true IL299750A (en) 2023-03-01

Family

ID=79552114

Family Applications (1)

Application Number Title Priority Date Filing Date
IL299750A IL299750A (en) 2020-07-10 2021-07-08 Lipid nanoparticles for the delivery of therapeutic agents to the lungs

Country Status (10)

Country Link
US (1) US20240065982A1 (cg-RX-API-DMAC7.html)
EP (1) EP4178585A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023534206A (cg-RX-API-DMAC7.html)
KR (1) KR20230038217A (cg-RX-API-DMAC7.html)
CN (1) CN115768438A (cg-RX-API-DMAC7.html)
AU (1) AU2021305214A1 (cg-RX-API-DMAC7.html)
CA (1) CA3188661A1 (cg-RX-API-DMAC7.html)
IL (1) IL299750A (cg-RX-API-DMAC7.html)
MX (1) MX2023000511A (cg-RX-API-DMAC7.html)
WO (1) WO2022011156A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019376006B2 (en) 2018-11-09 2026-07-02 Arbutus Biopharma Corporation Cationic lipids containing silicon
CZ310613B6 (cs) 2020-09-23 2026-01-28 Ústav organické chemie a biochemie AV ČR, v. v. i. Lipidoidy pro transfekci nukleových kyselin a jejich použití
CZ310443B6 (cs) 2021-07-19 2025-06-25 Ústav organické chemie a biochemie AV ČR, v. v. i. Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití
US12011507B2 (en) 2022-04-01 2024-06-18 Nanovation Therapeutics Inc. MRNA delivery composition
WO2024086929A1 (en) * 2022-10-25 2024-05-02 Nanovation Therapeutics Inc. Lipid nanoparticle formulations for anti-sense oligonucleotide delivery
WO2025133951A1 (en) * 2023-12-21 2025-06-26 Genevant Sciences Gmbh Ionizable lipids suitable for lipid nanoparticles
AU2025217182A1 (en) 2024-02-02 2026-08-06 Editas Medicine, Inc. MODIFIED GUIDE RNAs
WO2025213138A1 (en) 2024-04-05 2025-10-09 Editas Medicine, Inc. Crispr/rna-guided nuclease related methods and compositions for treating primary open angle glaucoma
CN118576568B (zh) * 2024-08-06 2024-11-26 北京悦康科创医药科技股份有限公司 一种药物组合物及其制备方法和应用
CN121622610A (zh) * 2024-09-05 2026-03-10 苏州慧疗生物医药科技有限公司 向细胞内递送遗传物质的三组分脂质纳米颗粒及组合物
WO2026102260A1 (en) 2024-11-08 2026-05-15 Editas Medicine, Inc. Crispr-related methods and compositions targeting angiopoietin like 3 (angptl3)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2279254B1 (en) * 2008-04-15 2017-07-05 Protiva Biotherapeutics Inc. Novel lipid formulations for nucleic acid delivery
ES2898340T3 (es) * 2015-07-09 2022-03-07 Insmed Inc Composiciones y métodos para tratar neumopatías y lesión pulmonar
GB2596224B (en) * 2018-06-19 2022-09-07 Univ Texas Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids
DE102018127300A1 (de) * 2018-10-31 2020-04-30 Henkel Ag & Co. Kgaa Wirkstoffzusammensetzung zum Schutz künstlich gefärbter Haare
AU2019376006B2 (en) * 2018-11-09 2026-07-02 Arbutus Biopharma Corporation Cationic lipids containing silicon
WO2020219941A1 (en) * 2019-04-26 2020-10-29 Genevant Sciences Gmbh Lipid nanoparticles

Also Published As

Publication number Publication date
WO2022011156A1 (en) 2022-01-13
AU2021305214A1 (en) 2023-02-23
EP4178585A1 (en) 2023-05-17
MX2023000511A (es) 2023-02-13
JP2023534206A (ja) 2023-08-08
KR20230038217A (ko) 2023-03-17
CA3188661A1 (en) 2022-01-13
CN115768438A (zh) 2023-03-07
WO2022011156A9 (en) 2022-03-17
US20240065982A1 (en) 2024-02-29
EP4178585A4 (en) 2024-11-20

Similar Documents

Publication Publication Date Title
EP4178585A4 (en) LIPID DNA PARTICLES FOR DELIVERY OF THERAPEUTICS TO THE LUNGS
PH12015500686A1 (en) Nicotine composition
DK3284459T3 (en) Pharmaceutical compositions comprising a local anaesthetic such as Bupivacaine for local administration to the mouth or throat
EP2661273A4 (en) IRON PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION
IL232762A0 (en) Aerosol device for inhalation of drugs that does not depend on the drug profile
MY168300A (en) Pharmaceutical Composition for Inhalation
PT2661275T (pt) Composições e métodos para a entrega a tumores de agentes ligantes de elevada afinidade para o oxigénio
IL212801A (en) Lipids and drug transfer compounds
EP2544742A4 (en) APPARATUS AND METHOD FOR THE DELIVERY OF LUNG AEROSOL OR OTHER BODY LOCATIONS
PL2755498T3 (pl) Kompozycja do podawania doustnego zwierzętom i sposób jej wytwarzania
EP2836501A4 (en) RNA APTAMERS FOR THERAPEUTIC AND DIAGNOSTIC ADMINISTRATION ON PANCREAS CRAB CELLS
EP2370068A4 (en) METHOD AND COMPOSITIONS FOR DELIVERING MEDICAMENTS TO THE LUNG
EP2688628A4 (en) DISCHARGE OF DILUTED OXYGEN TO A PATIENT
IL227666A0 (en) Aclidinium for use in improving the quality of sleep in respiratory patients
PL3369429T3 (pl) Kompozycja farmaceutyczna przeznaczona do podawania na błonę śluzową nosa
HK40084784A (en) Lipid nanoparticles for delivering therapeutics to lungs
EP2866792A4 (en) MICROPARTICLE FORMULATIONS FOR DELIVERY TO LOWER AND CENTRAL RESPIRATORY PATHS AND METHOD OF PREPARING THEM
GB2509476A (en) 18F - Fluciclovine compositions in citrate buffers
EP3065705A4 (en) Compositions and methods for administration of an enzyme to a subject's airway
ZA201308158B (en) Improved suspension formulation of a corticosteroid for administration by inhalation
ZA201401921B (en) Pharmaceutical composition of oxidised avidin suitable for inhalation
GB201111226D0 (en) Improvements in relating to urological catheters
PH12012000220A1 (en) Solid pharmaceutical composition for buccal administration of agomelatine
PL2575323T3 (pl) Dostarczanie treści od serwera do klienta
SG11201501020WA (en) Pharmaceutical composition for increasing content and availability of cyclic adenosine monophosphate in a body and the preparation thereof